Panbela TherapeuticsのCurrent ratio
Panbela TherapeuticsのCurrent ratioは何ですか。
Panbela Therapeutics Inc.のCurrent ratioは0.21です。
Current ratioの定義は何ですか。
流動比率は、同社が短期債務を履行するために十分なリソースを持っているかどうかを測定流動性比率です。
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
NASDAQのセクタHealth CareにおけるCurrent ratioの企業と比べるPanbela Therapeutics
Panbela Therapeuticsは何をしますか。
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Panbela Therapeuticsと類似のcurrent ratio
- Integrated Finl Hldgs IncのCurrent ratioは0.21です。
- Westpac BankingのCurrent ratioは0.21です。
- SugarBud Craft GrowersのCurrent ratioは0.21です。
- AllianceBernstein National Municipal Income Fund IncのCurrent ratioは0.21です。
- Cannabis Strategic VenturesのCurrent ratioは0.21です。
- Guangzhou Rural Commercial Bank CoのCurrent ratioは0.21です。
- Panbela TherapeuticsのCurrent ratioは0.21です。
- BlackRock Muni Quality Fund II IncのCurrent ratioは0.21です。
- Rainy Mountain RoyaltyのCurrent ratioは0.21です。
- Cullen/Frost BankersのCurrent ratioは0.21です。
- Videocon IndustriesのCurrent ratioは0.21です。
- Home Invest Belgium S.AのCurrent ratioは0.21です。
- Cannabis Global, IncのCurrent ratioは0.21です。